Last reviewed · How we verify
Hyundai Pharmaceutical Co., LTD. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| BPDO-1603 | BPDO-1603 | phase 3 | ACE inhibitor | ACE | Cardiovascular | |
| Acebrophylline | Acebrophylline | phase 3 | Other |
Therapeutic area mix
- Cardiovascular · 1
- Other · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Beijing Tide Pharmaceutical Co., Ltd · 1 shared drug class
- Bioprojet · 1 shared drug class
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- Children's Hospital of Fudan University · 1 shared drug class
- Ace Cells Lab Limited · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Hyundai Pharmaceutical Co., LTD.:
- Hyundai Pharmaceutical Co., LTD. pipeline updates — RSS
- Hyundai Pharmaceutical Co., LTD. pipeline updates — Atom
- Hyundai Pharmaceutical Co., LTD. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Hyundai Pharmaceutical Co., LTD. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hyundai-pharmaceutical-co-ltd. Accessed 2026-05-16.